A Phase Ib Study of YY-20394 in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma

NCT04108325 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

58

Enrollment

INDUSTRY

Sponsor class

Conditions

Relapsed or Refractory Peripheral T-Cell Lymphoma

Interventions

DRUG: YY-20394

Sponsor

Shanghai YingLi Pharmaceutical Co. Ltd.